BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Efficace F, Collins GS, Cottone F, Giesinger JM, Sommer K, Anota A, Schlussel MM, Fazi P, Vignetti M. Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis. Value in Health 2021;24:250-67. [DOI: 10.1016/j.jval.2020.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
3 Das A, Gabr A, O'Brian DP, Riaz A, Desai K, Thornburg B, Kallini JR, Mouli S, Lewandowski RJ, Salem R. Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30:1924-1933.e2. [PMID: 31685362 DOI: 10.1016/j.jvir.2019.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wohlleber K, Heger P, Probst P, Engel C, Diener MK, Mihaljevic AL. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Qual Life Res 2021;30:2429-66. [PMID: 34283381 DOI: 10.1007/s11136-021-02810-8] [Reference Citation Analysis]
5 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
6 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
8 Goislard de Monsabert C, Touchefeu Y, Guiu B, Campillo-Gimenez B, Farges O, Tougeron D, Baumgaertner I, Ayav A, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Garin E, Boucher E, Edeline J. Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. Curr Oncol 2021;28:4530-41. [PMID: 34898592 DOI: 10.3390/curroncol28060384] [Reference Citation Analysis]
9 Moctezuma-Velazquez C, Montano-Loza AJ, Meza-Junco J, Burak K, Ma M, Bain VG, Kneteman N, Sarlieve P, Owen RJ. Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages. Dig Dis Sci 2021;66:899-911. [PMID: 32281043 DOI: 10.1007/s10620-020-06245-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pereira H, Bouattour M, Dioguardi Burgio M, Assenat E, Grégory J, Bronowicki JP, Chatellier G, Vilgrain V; SARAH Trial Group. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer 2021;154:46-56. [PMID: 34243077 DOI: 10.1016/j.ejca.2021.05.032] [Reference Citation Analysis]
11 Kang D, Shim S, Cho J, Lim HK. Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018. Korean J Radiol 2020;21:633-46. [PMID: 32410403 DOI: 10.3348/kjr.2019.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 van Roekel C, Smits MLJ, Prince JF, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Quality of life in patients with liver tumors treated with holmium-166 radioembolization. Clin Exp Metastasis 2020;37:95-105. [PMID: 31732841 DOI: 10.1007/s10585-019-10006-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wehling C, Hornuss D, Schneider P, Springfeld C, Hoffmann K, Chang D, Naumann P, Mieth M, Longerich T, Kratochwil C, Mehrabi A, Gauss A, Weiss KH, Pfeiffenberger J. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:2761-9. [DOI: 10.1007/s00432-019-03005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:649-58. [PMID: 34087115 DOI: 10.1016/S2468-1253(21)00110-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Williams SJ, Rilling WS, White SB. Quality of Life and Cost Considerations: Y-90 Radioembolization. Semin Intervent Radiol 2021;38:482-7. [PMID: 34629718 DOI: 10.1055/s-0041-1735570] [Reference Citation Analysis]
16 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]